Chimeric Antigen Receptors for the Tumour Microenvironment View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2020-06-26

AUTHORS

Rosemary Habib , Adnan Nagrial , Kenneth Micklethwaite , Kavitha Gowrishankar

ABSTRACT

Chimeric antigen receptor T (CAR-T) cell therapy has dramatically revolutionised cancer treatment. The FDA approval of two CAR-T cell products for otherwise incurable refractory B-cell acute lymphoblastic leukaemia (B-ALL) and aggressive B-cell non-Hodgkin lymphoma has established this treatment as an effective immunotherapy option. The race for extending CAR-T therapy for various tumours is well and truly underway. However, response rates in solid organ cancers have been inadequate thus far, partly due to challenges posed by the tumour microenvironment (TME). The TME is a complex structure whose role is to subserve the persistence and proliferation of tumours as well as support their escape from immune surveillance. It presents several obstacles like inhibitory immune checkpoint proteins, immunosuppressive cells, cytokines, chemokines, stromal factors and adverse metabolic pathways. CAR structure and CAR-T therapies have evolved to overcome these obstacles, and we now have several novel CARs with improved anti-tumour activity demonstrated in xenograft models and in some clinical trials. This chapter provides a discussion of the evolution of CAR-T therapies to enable targeting specific aspects of the TME. More... »

PAGES

117-143

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-030-44518-8_8

DOI

http://dx.doi.org/10.1007/978-3-030-44518-8_8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1128774775

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32588326


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy, Adoptive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Chimeric Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "T-Lymphocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Microenvironment", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413252.3", 
          "name": [
            "Westmead Institute for Medical Research, The\u00a0University of Sydney, Sydney, NSW, Australia", 
            "Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Habib", 
        "givenName": "Rosemary", 
        "id": "sg:person.010155043227.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010155043227.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413252.3", 
          "name": [
            "Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nagrial", 
        "givenName": "Adnan", 
        "id": "sg:person.01142566126.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142566126.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sydney Cellular Therapies Laboratory, Blood and Bone Marrow Transplant Unit, Department of Haematology, Sydney Medical School, Westmead Hospital, Sydney, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.413252.3", 
          "name": [
            "Westmead Institute for Medical Research, The\u00a0University of Sydney, Sydney, NSW, Australia", 
            "Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia", 
            "Sydney Cellular Therapies Laboratory, Blood and Bone Marrow Transplant Unit, Department of Haematology, Sydney Medical School, Westmead Hospital, Sydney, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Micklethwaite", 
        "givenName": "Kenneth", 
        "id": "sg:person.01170027105.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170027105.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Westmead Institute for Medical Research, The\u00a0University of Sydney, Sydney, NSW, Australia", 
          "id": "http://www.grid.ac/institutes/grid.452919.2", 
          "name": [
            "Westmead Institute for Medical Research, The\u00a0University of Sydney, Sydney, NSW, Australia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gowrishankar", 
        "givenName": "Kavitha", 
        "id": "sg:person.01125632101.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125632101.34"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2020-06-26", 
    "datePublishedReg": "2020-06-26", 
    "description": "Chimeric antigen receptor T (CAR-T) cell therapy has dramatically revolutionised cancer treatment. The FDA approval of two CAR-T cell products for otherwise incurable refractory B-cell acute lymphoblastic leukaemia (B-ALL) and aggressive B-cell non-Hodgkin lymphoma has established this treatment as an effective immunotherapy option. The race for extending CAR-T therapy for various tumours is well and truly underway. However, response rates in solid organ cancers have been inadequate thus far, partly due to challenges posed by the tumour microenvironment (TME). The TME is a complex structure whose role is to subserve the persistence and proliferation of tumours as well as support their escape from immune surveillance. It presents several obstacles like inhibitory immune checkpoint proteins, immunosuppressive cells, cytokines, chemokines, stromal factors and adverse metabolic pathways. CAR structure and CAR-T therapies have evolved to overcome these obstacles, and we now have several novel CARs with improved anti-tumour activity demonstrated in xenograft models and in some clinical trials. This chapter provides a discussion of the evolution of CAR-T therapies to enable targeting specific aspects of the TME.", 
    "editor": [
      {
        "familyName": "Birbrair", 
        "givenName": "Alexander", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-030-44518-8_8", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-3-030-44517-1", 
        "978-3-030-44518-8"
      ], 
      "name": "Tumor Microenvironment", 
      "type": "Book"
    }, 
    "keywords": [
      "B-cell acute lymphoblastic leukemia", 
      "CAR-T therapy", 
      "tumor microenvironment", 
      "refractory B-cell acute lymphoblastic leukemia", 
      "chimeric antigen receptor T-cell therapy", 
      "aggressive B-cell non-Hodgkin lymphoma", 
      "B-cell non-Hodgkin lymphoma", 
      "CAR T-cell products", 
      "inhibitory immune checkpoint proteins", 
      "solid organ cancers", 
      "T-cell therapy", 
      "non-Hodgkin lymphoma", 
      "improved anti-tumor activity", 
      "acute lymphoblastic leukemia", 
      "immune checkpoint proteins", 
      "chimeric antigen receptor", 
      "proliferation of tumors", 
      "anti-tumor activity", 
      "immunotherapy options", 
      "immunosuppressive cells", 
      "organ cancers", 
      "lymphoblastic leukemia", 
      "clinical trials", 
      "immune surveillance", 
      "xenograft model", 
      "response rate", 
      "FDA approval", 
      "cell therapy", 
      "cancer treatment", 
      "antigen receptor", 
      "stromal factors", 
      "therapy", 
      "cell products", 
      "novel CAR", 
      "tumors", 
      "treatment", 
      "microenvironment", 
      "metabolic pathways", 
      "chemokines", 
      "lymphoma", 
      "checkpoint proteins", 
      "cytokines", 
      "leukemia", 
      "cancer", 
      "trials", 
      "receptors", 
      "surveillance", 
      "proliferation", 
      "approval", 
      "specific aspects", 
      "cells", 
      "options", 
      "pathway", 
      "factors", 
      "protein", 
      "activity", 
      "race", 
      "role", 
      "persistence", 
      "rate", 
      "car structure", 
      "escape", 
      "challenges", 
      "obstacles", 
      "aspects", 
      "discussion", 
      "model", 
      "products", 
      "chapter", 
      "structure", 
      "cars", 
      "evolution", 
      "complex structure"
    ], 
    "name": "Chimeric Antigen Receptors for the Tumour Microenvironment", 
    "pagination": "117-143", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1128774775"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-030-44518-8_8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32588326"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-030-44518-8_8", 
      "https://app.dimensions.ai/details/publication/pub.1128774775"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-09-02T16:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/chapter/chapter_315.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-030-44518-8_8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-44518-8_8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-44518-8_8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-44518-8_8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-030-44518-8_8'


 

This table displays all metadata directly associated to this object as RDF triples.

191 TRIPLES      22 PREDICATES      104 URIs      96 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-030-44518-8_8 schema:about N1059d566efb64292996810d088edbe13
2 N26dfc08e0058445b9c25b4fba435a181
3 N5d52bf602d2544ac85626bb6fe81abe1
4 N79d0fb93e7fc45238db25f3931748fc4
5 Nf5aa3f921c9a478885d2d504323acc8e
6 Nf5fc23878f9a47f7ba674c6e7ee592b5
7 anzsrc-for:11
8 anzsrc-for:1107
9 anzsrc-for:1112
10 schema:author N8568d6c53fb64fb79dd666e0e7f58cc2
11 schema:datePublished 2020-06-26
12 schema:datePublishedReg 2020-06-26
13 schema:description Chimeric antigen receptor T (CAR-T) cell therapy has dramatically revolutionised cancer treatment. The FDA approval of two CAR-T cell products for otherwise incurable refractory B-cell acute lymphoblastic leukaemia (B-ALL) and aggressive B-cell non-Hodgkin lymphoma has established this treatment as an effective immunotherapy option. The race for extending CAR-T therapy for various tumours is well and truly underway. However, response rates in solid organ cancers have been inadequate thus far, partly due to challenges posed by the tumour microenvironment (TME). The TME is a complex structure whose role is to subserve the persistence and proliferation of tumours as well as support their escape from immune surveillance. It presents several obstacles like inhibitory immune checkpoint proteins, immunosuppressive cells, cytokines, chemokines, stromal factors and adverse metabolic pathways. CAR structure and CAR-T therapies have evolved to overcome these obstacles, and we now have several novel CARs with improved anti-tumour activity demonstrated in xenograft models and in some clinical trials. This chapter provides a discussion of the evolution of CAR-T therapies to enable targeting specific aspects of the TME.
14 schema:editor N7490843db50845518b68748195ef0e40
15 schema:genre chapter
16 schema:isAccessibleForFree false
17 schema:isPartOf Nba06fbc1cafe4ea6a1882abddef1a665
18 schema:keywords B-cell acute lymphoblastic leukemia
19 B-cell non-Hodgkin lymphoma
20 CAR T-cell products
21 CAR-T therapy
22 FDA approval
23 T-cell therapy
24 activity
25 acute lymphoblastic leukemia
26 aggressive B-cell non-Hodgkin lymphoma
27 anti-tumor activity
28 antigen receptor
29 approval
30 aspects
31 cancer
32 cancer treatment
33 car structure
34 cars
35 cell products
36 cell therapy
37 cells
38 challenges
39 chapter
40 checkpoint proteins
41 chemokines
42 chimeric antigen receptor
43 chimeric antigen receptor T-cell therapy
44 clinical trials
45 complex structure
46 cytokines
47 discussion
48 escape
49 evolution
50 factors
51 immune checkpoint proteins
52 immune surveillance
53 immunosuppressive cells
54 immunotherapy options
55 improved anti-tumor activity
56 inhibitory immune checkpoint proteins
57 leukemia
58 lymphoblastic leukemia
59 lymphoma
60 metabolic pathways
61 microenvironment
62 model
63 non-Hodgkin lymphoma
64 novel CAR
65 obstacles
66 options
67 organ cancers
68 pathway
69 persistence
70 products
71 proliferation
72 proliferation of tumors
73 protein
74 race
75 rate
76 receptors
77 refractory B-cell acute lymphoblastic leukemia
78 response rate
79 role
80 solid organ cancers
81 specific aspects
82 stromal factors
83 structure
84 surveillance
85 therapy
86 treatment
87 trials
88 tumor microenvironment
89 tumors
90 xenograft model
91 schema:name Chimeric Antigen Receptors for the Tumour Microenvironment
92 schema:pagination 117-143
93 schema:productId N4010852f45ab4c0f95d393095c14e6de
94 N6c746e5050a1457cab06ec24af7c1530
95 Nf7b2fd49033649c393375d974f1d28b9
96 schema:publisher Ne629d6159b044fac8890f0087b7ca942
97 schema:sameAs https://app.dimensions.ai/details/publication/pub.1128774775
98 https://doi.org/10.1007/978-3-030-44518-8_8
99 schema:sdDatePublished 2022-09-02T16:14
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher N4bf9bcf141fa4483b1840818f8d5be2a
102 schema:url https://doi.org/10.1007/978-3-030-44518-8_8
103 sgo:license sg:explorer/license/
104 sgo:sdDataset chapters
105 rdf:type schema:Chapter
106 N1059d566efb64292996810d088edbe13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Immunotherapy, Adoptive
108 rdf:type schema:DefinedTerm
109 N26dfc08e0058445b9c25b4fba435a181 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Neoplasms
111 rdf:type schema:DefinedTerm
112 N4010852f45ab4c0f95d393095c14e6de schema:name dimensions_id
113 schema:value pub.1128774775
114 rdf:type schema:PropertyValue
115 N4bf9bcf141fa4483b1840818f8d5be2a schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 N5d29cc071c7e417c83ab44bbff74ed91 schema:familyName Birbrair
118 schema:givenName Alexander
119 rdf:type schema:Person
120 N5d52bf602d2544ac85626bb6fe81abe1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name T-Lymphocytes
122 rdf:type schema:DefinedTerm
123 N6c746e5050a1457cab06ec24af7c1530 schema:name pubmed_id
124 schema:value 32588326
125 rdf:type schema:PropertyValue
126 N7490843db50845518b68748195ef0e40 rdf:first N5d29cc071c7e417c83ab44bbff74ed91
127 rdf:rest rdf:nil
128 N79d0fb93e7fc45238db25f3931748fc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Tumor Microenvironment
130 rdf:type schema:DefinedTerm
131 N80336993494e49e9b7ed600d4490ebc2 rdf:first sg:person.01125632101.34
132 rdf:rest rdf:nil
133 N8568d6c53fb64fb79dd666e0e7f58cc2 rdf:first sg:person.010155043227.42
134 rdf:rest Nec9cf70bffbd4b478b9b0e814b1be70c
135 Nb4b077a4987e4864b444b47dc2ace1de rdf:first sg:person.01170027105.59
136 rdf:rest N80336993494e49e9b7ed600d4490ebc2
137 Nba06fbc1cafe4ea6a1882abddef1a665 schema:isbn 978-3-030-44517-1
138 978-3-030-44518-8
139 schema:name Tumor Microenvironment
140 rdf:type schema:Book
141 Ne629d6159b044fac8890f0087b7ca942 schema:name Springer Nature
142 rdf:type schema:Organisation
143 Nec9cf70bffbd4b478b9b0e814b1be70c rdf:first sg:person.01142566126.25
144 rdf:rest Nb4b077a4987e4864b444b47dc2ace1de
145 Nf5aa3f921c9a478885d2d504323acc8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Humans
147 rdf:type schema:DefinedTerm
148 Nf5fc23878f9a47f7ba674c6e7ee592b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Receptors, Chimeric Antigen
150 rdf:type schema:DefinedTerm
151 Nf7b2fd49033649c393375d974f1d28b9 schema:name doi
152 schema:value 10.1007/978-3-030-44518-8_8
153 rdf:type schema:PropertyValue
154 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
155 schema:name Medical and Health Sciences
156 rdf:type schema:DefinedTerm
157 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
158 schema:name Immunology
159 rdf:type schema:DefinedTerm
160 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
161 schema:name Oncology and Carcinogenesis
162 rdf:type schema:DefinedTerm
163 sg:person.010155043227.42 schema:affiliation grid-institutes:grid.413252.3
164 schema:familyName Habib
165 schema:givenName Rosemary
166 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010155043227.42
167 rdf:type schema:Person
168 sg:person.01125632101.34 schema:affiliation grid-institutes:grid.452919.2
169 schema:familyName Gowrishankar
170 schema:givenName Kavitha
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125632101.34
172 rdf:type schema:Person
173 sg:person.01142566126.25 schema:affiliation grid-institutes:grid.413252.3
174 schema:familyName Nagrial
175 schema:givenName Adnan
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142566126.25
177 rdf:type schema:Person
178 sg:person.01170027105.59 schema:affiliation grid-institutes:grid.413252.3
179 schema:familyName Micklethwaite
180 schema:givenName Kenneth
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170027105.59
182 rdf:type schema:Person
183 grid-institutes:grid.413252.3 schema:alternateName Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia
184 Sydney Cellular Therapies Laboratory, Blood and Bone Marrow Transplant Unit, Department of Haematology, Sydney Medical School, Westmead Hospital, Sydney, NSW, Australia
185 schema:name Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia
186 Sydney Cellular Therapies Laboratory, Blood and Bone Marrow Transplant Unit, Department of Haematology, Sydney Medical School, Westmead Hospital, Sydney, NSW, Australia
187 Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia
188 rdf:type schema:Organization
189 grid-institutes:grid.452919.2 schema:alternateName Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia
190 schema:name Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia
191 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...